Vicore Pharma strengthens team with two key hires to support focus on rare lung disease
September 17, 2018 - Vicore Pharma (publ) announced today it has appointed Rohit Batta as Chief Medical Officer effective November 26 and Göran Tornling as Senior Medical Advisor starting September 17. Dr. Batta will report to the CEO and join the Vicore Pharma Executive Team. Both recruitments are important to bolster Vicore’s medical competencies in the pulmonary rare disease space.
Dr. Rohit Batta has 18 years of experience as a medical doctor with an extensive background, leading medical and clinical development teams whilst developing drugs for rare diseases. His previous roles include Senior Director of Cell and Gene Therapy at GlaxoSmithKline (GSK) with responsibility for leading the clinical development team and defining the clinical strategy for haemoglobinopathy gene therapy medicines. He also led the global medical and late stage clinical development teams to launch the world’s first gene therapy for patients with a pediatric rare disease.
Dr. Batta holds an MBBS from Kings College School of Medicine and is a member to the Royal College of General Practitioners and to the Faculty of Pharmaceutical Medicine.
Dr. Göran Tornling has almost four decades’ experience as a physician specializing in respiratory medicine. His previous roles include Executive Director Clinical Science and Strategy (Respiratory) at AstraZeneca R&D with responsibility for developing clinical strategies, including an IPF program which is Vicore’s main indication. He was EVP and Head Research and Development at Orexo, responsible for research and preclinical development and pharmaceutical innovation and development.
Dr. Tornling is a graduate of Sweden’s Royal Institute of Technology and Karolinska Institutet and is a certified specialist in respiratory and occupational medicine.
“Batta and Tornling are top-notch minds in their space and are passionate about helping people in need – exactly the type of capabilities Vicore needs to form its world-class medical team and continue the development momentum in our clinical programs”, said Vicore Pharma’s CEO, Dr. Carl-Johan Dalsgaard.
For further information, please contact:
Dr. Carl-Johan Dalsgaard, CEO: +46 709 759 863, email@example.com